Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
People with severe mental illness (SMI) have higher risks for COVID-19 infection, hospitalization, and mortality.
In a recent survey, more than half the college students with ADHD had at least 1 psychiatric disorder. The recent WHO World Mental Health Survey of college students assessed comorbidities in more than 15,000 college freshmen across 9 countries.
Researchers sought to investigate the association between lower retinal nerve fiber layer thickness, a marker of neurodegeneration, with clinically relevant depressive symptoms and depressive symptoms over time.
Cognitive behavioral therapy for insomnia (CBT-I) has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Universal school-based MDD screening increases identification of adolescents with MDD symptoms and initiation of treatment.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
The FDA has cleared Nexstim's NBT system for the treatment of major depressive disorder.
Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.